DESFLURANE - Generic Drug Details

What are the generic sources for desflurane and what is the scope of patent protection?

Desflurane is the generic ingredient in two branded drugs marketed by Shanghai Hengrui and Baxter Hlthcare, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for desflurane. Four suppliers are listed for this compound.

Summary for DESFLURANE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	256
Patent Applications:	2,311
What excipients (inactive ingredients) are in DESFLURANE?	DESFLURANE excipients list
DailyMed Link:	DESFLURANE at DailyMed

Recent Clinical Trials for DESFLURANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ajou University School of Medicine	N/A
Jason Chui	Phase 4
King Saud Medical City	Phase 3

See all DESFLURANE clinical trials

Pharmacology for DESFLURANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Anatomical Therapeutic Chemical (ATC) Classes for DESFLURANE

N01AB	Halogenated hydrocarbons
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

Paragraph IV (Patent) Challenges for DESFLURANE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUPRANE	Inhalation	desflurane	99.9%	020118	1	2008-09-11

US Patents and Regulatory Information for DESFLURANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shanghai Hengrui	DESFLURANE	desflurane	LIQUID;INHALATION	208234-001	Feb 26, 2018	AN	RX	No	No
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	AN	RX	Yes	Yes

Expired US Patents for DESFLURANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	4,762,856*PED
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	5,617,906*PED

DESFLURANE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Desflurane

Market Size and Growth

The global inhalation anesthesia market, which includes desflurane, is projected to experience significant growth over the coming years. As of 2024, the global inhalation anesthesia market was estimated at USD 1.51 billion and is expected to grow at a CAGR of 6.65% from 2025 to 2030, reaching USD 2.22 billion by 2030[1].

Desflurane Segment Growth

Desflurane, a volatile inhalation anesthetic, is a key player in this market. Despite not dominating the market share like sevoflurane, desflurane is growing significantly. It is known for its rapid induction and recovery times, making it a preferred choice in both adult and pediatric surgeries. Desflurane's low blood/gas solubility allows for swift adjustments in anesthesia depth, which is highly advantageous in longer surgeries or cases requiring careful monitoring, such as in elderly or obese patients[1].

Pharmacokinetic Properties

Desflurane's favorable pharmacokinetic properties, including its ability to maintain stable hemodynamics during procedures, contribute to its growing adoption. These characteristics make it especially useful in outpatient settings and surgeries that demand quick patient recovery. However, its higher cost and pungency, which can cause respiratory irritation, limit its use compared to sevoflurane[3].

Environmental and Financial Impact

The use of desflurane has been under scrutiny due to its high global warming potential (GWP) and financial costs. An initiative by an academic medical center to reduce desflurane use resulted in significant financial and environmental benefits. By shifting to sevoflurane, the center reduced total purchasing costs of volatile anesthetics by 60.9% and decreased CO2 equivalents (CO2E) production by 84.8%[2].

Cost Analysis

Studies have shown that using low-flow fresh gas flow rates (FGFR) with desflurane can significantly reduce costs. An audit study found that the calculated savings per patient with low-flow desflurane anesthesia compared to high-flow desflurane anesthesia was 109.25 AED (United Arab Emirates Dirham)[5].

Regional Market Dynamics

While desflurane is being phased out in some regions like Europe, its demand is expected to remain in other areas. In Latin America, for instance, manufacturers may prioritize the production and distribution of other anesthetic agents, but desflurane could still find a market due to its specific benefits[1].

Competitive Landscape

The market for inhalation anesthetics, including desflurane, is competitive with several key players such as Baxter, Abbvie Inc, Halocarbon Product Corporation, Sandoz International GmbH, and Piramal Enterprises Ltd. Recent acquisitions, such as Dechra's acquisition of Isoflurane and Sevoflurane products from Halocarbon Life Sciences, indicate ongoing market activities and strategic shifts[1][4].

Future Trends

The shift towards more sustainable and cost-effective anesthetic agents is a significant trend. As healthcare providers prioritize sustainability alongside efficacy, the demand for agents like desflurane, despite its environmental impact, will be influenced by innovations in anesthesia technology that optimize delivery and effectiveness. However, the market is likely to see a continued preference for sevoflurane due to its broader acceptance and favorable pharmacokinetic properties[3].

Regulatory and Approval Landscape

Regulatory approvals and partnerships also play a crucial role in the market dynamics. For example, Blue-Zone Technologies Ltd. received a Drug Identification Number (DIN) from Health Canada for Desflurane, USP, allowing the company to manufacture and market its branded generic medicine[4].

Financial Trajectory

Despite the higher costs associated with desflurane, its financial trajectory is tied to the overall growth of the inhalation anesthesia market. The market's expected growth at a CAGR of 6.65% from 2025 to 2030 indicates that desflurane, while not the dominant player, will still contribute to the market's financial expansion. However, efforts to reduce its use due to environmental and financial concerns may impact its specific financial trajectory negatively compared to other agents like sevoflurane[1].

Key Takeaways

• Growth Potential: Desflurane is growing significantly due to its rapid induction and recovery times.
• Pharmacokinetic Properties: Its low blood/gas solubility and stable hemodynamics make it useful in various surgical settings.
• Environmental Impact: High GWP and financial costs are driving efforts to reduce its use.
• Cost Savings: Low-flow FGFR techniques can significantly reduce costs associated with desflurane.
• Competitive Landscape: The market is competitive, with several key players influencing market dynamics.
• Future Trends: Innovations in anesthesia technology and sustainability priorities will shape its future use.

FAQs

Q: What are the key benefits of desflurane in surgical procedures? A: Desflurane offers rapid induction and recovery times, low blood/gas solubility allowing for swift adjustments in anesthesia depth, and stable hemodynamics during procedures.

Q: Why is desflurane being phased out in some regions? A: Desflurane is being phased out due to its high global warming potential (GWP) and higher financial costs compared to other anesthetic agents like sevoflurane.

Q: How can the use of desflurane be made more cost-effective? A: Using low-flow fresh gas flow rates (FGFR) with desflurane can significantly reduce costs.

Q: What is the expected market growth for desflurane in the coming years? A: The global inhalation anesthesia market, which includes desflurane, is expected to grow at a CAGR of 6.65% from 2025 to 2030.

Q: Which regions are expected to see continued demand for desflurane? A: Regions like Latin America and the Middle East and Africa (MEA) may continue to see demand for desflurane due to its specific benefits and market dynamics.

Sources

1. Grand View Research: Inhalation Anesthesia Market Size And Share Report, 2030
2. ASRA Newsletter: “Greening” the Operating Room and Your Budget by Reducing Desflurane Use
3. MarketResearch.biz: Inhalation Anesthesia Market Size, Share, Growth | CAGR of 9.2%
4. Mordor Intelligence: Inhalation Anesthesia Market - Trends, Growth, Share & Size
5. Journal of the Saudi Anesthesia Association: Precision in practice: An audit study on low-flow anesthesia[1][2][3][4][5]